Last reviewed · How we verify
NCT03127657
Effect of Cock's Comb Extract in the Treatment of Arsenical Skin Lesion
Phase 2 trial testing Cock's comb extract 0.01% in Chronic Arsenic Poisoning in 25 participants. Completed in 31 January 2018.
31 January 2018
Quick facts
| Lead sponsor | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 17 January 2016 |
| Primary completion | 31 January 2018 |
| Estimated completion | 31 January 2018 |
| Sites | 1 location across Bangladesh |
Drugs / interventions tested
- Cock's comb extract 0.01% — full drug profile →
Conditions studied
- Chronic Arsenic Poisoning — all drugs for Chronic Arsenic Poisoning →
Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Who can join
Adults 18 to 60, any sex, with Chronic Arsenic Poisoning. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cock's comb extract is rich in hyaluronic acid, which is used as viscosupplementation injection and oral supplementation for osteoarthritis. Hyaluronic acid acts as humectants and topical moisturizing agent to the skin due to excellent moisturizing property. It has anti-inflammatory effect and used in the treatment of ulcer healing and to reduce the intensity of radioepithelitis. It is also used as a topical vehicle for the delivery of drug to the skin in actinic keratosis. In the case of arsenical keratotic nodule, topical application of hyaluronic acid may tends to decrease keratosis by repeated hydration of the skin. Therefore, the study will be conducted to determine any beneficial effect of topical application of cock's comb extract in the treatment of the patients with severe palmar arsenical keratosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03127657
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh trials
Trials by the same sponsor.
- NCT07507045 — Education-Based Oral Health Promotion Intervention During Pregnancy: Implementation Protocol in Bangladesh · NA · not yet recruiting
- NCT07537634 — Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication · Phase 4 · not yet recruiting
- NCT07161336 — Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA · Phase 2 · recruiting
- NCT06960694 — Effect of L-carnitine on Disease Activity in Patients With Mild to Moderate Knee Osteoarthritis · Phase 2 · completed
- NCT07123922 — Effect of Silymarin as Add on Therapy on Oxidative Stress, Pulmonary Function and Quality of Life in Stable COPD Patient · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03127657 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Last refreshed: 13 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03127657.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing